JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Intervention - Low Risk Group OR Intermediate Risk Group.
- Who it may be relevant to
- Registry conditions: Cardiovascular Health, Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Cardio-oncology. Basic parameters: 18 years — 79 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year (JUSTIFY): a Randomized Controlled Trial
Overview
This study focuses on male and female patients being treated for breast cancer that is positive for the HER2 receptor which requires special treatments targeting that receptor. The problem is that these treatments, while effective for the cancer, can sometimes harm the heart. Because of this, patients have to undergo heart tests every three months during treatment, even if they have no history of heart disease or feel fine. The guidelines for these regular heart tests were established decades ago when these treatments were first introduced, but research shows that most of these tests don't actually change the treatment plan. This suggests that many patients are going through unnecessary tests, which can cause stress, delay treatments, and increase healthcare costs. To address this, the researchers propose a new study with 300 patients with HER2 positive breast cancer to test a more personalized approach to cardiac surveillance. Participants will be classified based on their risk of heart problems: low or intermediate. Instead of testing every patient every three months, those in the intermediate group will be tested every 4 months, and those in the low-risk group will be tested every 6 months. The researchers will compare this new approach to the current system to see if fewer tests are just as safe and effective. The researchers will measure heart health, how well cancer treatments are completed, and how patients feel about having fewer tests. If this new approach works, it could save money and reduce the burden on female patients without risking their health.
Interventions
- Diagnostic test Intervention - Low Risk Group OR Intermediate Risk Group
Participants will be randomized to judicious imaging (decreased imaging frequency based on HF risk category) or SOC (imaging every 3 months). Participants who do not have any HF risk factors will be categorized as low risk, while participants with at least one risk factor will be categorized as intermediate risk for HF. Low Risk (zero risk factors): imaging before cycles 1 and 9 of HER2-TT (i.e., at baseline and near the halfway mark, corresponding to 2 fewer studies than SOC in Year 1), then a
Primary outcome measures
- Clinically overt heart failure [Time frame: From enrollment to <100days after end of treatment]
- Premature HER2TT discontinuation [Time frame: From enrollment to <100days after end of treatment]
- Patient-reported outcome measures (PROMS) of anxiety/depression, stress, and treatment burden [Time frame: From enrollment to <100 days after end of treatment]
- Asymptomatic cardiotoxicity at end of HER2TT [Time frame: From enrollment to <100 days after the end of treatment]
- Time to complete HER2TT [Time frame: From enrollment to <100 days after the end of treatment]
- Total number of cardiac imaging tests during HER2TT [Time frame: From enrollment to <100 days after the end of treatment]
Secondary outcome measures (2)
- Absolute change in percentage of LVEF [Time frame: From baseline imaging to one year]
- Desirability Ratio [Time frame: From enrollment to <100 days after the end of treatment]
Eligibility criteria
Inclusion criteria
- Stage 1-3 breast cancer (BC).
- Age 18-79 years.
- HER-2 positive BC with planned HER2 targeted therapy (HER2TT) for curative intent.
Exclusion criteria
- Distant metastases detected clinically, radiographically, or histologically
- Baseline echocardiogram images of insufficient quality for a quantitative assessment of left ventricular ejection fraction (LVEF)
- Pre-existing cardiovascular disease, defined as:
- Prior myocardial infarction (even if LVEF has normalized)
- Prior heart failure (HF, including patients with preserved ejection fraction and normalized LVEF)
- Baseline LVEF <55%
- Atrial fibrillation
- Greater than moderate valvular disease (i.e., severe, or moderate-severe)
- Cumulative anthracycline exposure ≥250mg/m2 before starting HER2TT
- New York Heart Association Functional Class II, III or IV, or Eastern Cooperative Oncology Group score >2\*
- Symptoms potentially due to serious cardiac disease as per investigator's judgement\* \*Exclusion criterion adopted as they make clinical assessment less reliable to detect emergent HF.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Screening
Study locations
Canada · 1 center
- Toronto General Hospital — Toronto
Identifiers
NCT: NCT06930521 · 5034